Aubrey Dobbs, MD
Internal Medicine · Lakewood, CONPI 1316007826
Payments from drug & device makers
Across 414 payments — averaging $15.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$879
- GSK$667
- AbbVie$631
- Pfizer$607
- AstraZeneca$592
- Lilly USA, LLC$469
- plus $3K from 30 others
What the payments were for
- Food & beverage$6,48398%
- Education$992%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 56 | $879 |
| GSK | 34 | $667 |
| AbbVie(2 entities) | 37 | $631 |
| Pfizer | 46 | $607 |
| AstraZeneca | 35 | $592 |
| Lilly USA, LLC | 55 | $469 |
| Amgen | 18 | $327 |
| Johnson & Johnson | 18 | $279 |
| Astellas Pharma US Inc | 10 | $259 |
| E.r. Squibb & Sons, L.L.C. | 13 | $244 |
| Merck | 17 | $190 |
| Amarin Pharma, Inc. | 8 | $143 |
| Otsuka America Pharmaceutical, Inc. | 6 | $137 |
| Bayer | 7 | $130 |
| Amneal Pharmaceuticals LLC | 7 | $121 |
| Sanofi-aventis U.S. LLC | 7 | $103 |
| Inspire Medical Systems, Inc. | 2 | $102 |
| Kowa Pharmaceuticals America, Inc. | 6 | $89 |
| Eisai Inc. | 5 | $86 |
| Novo Nordisk | 3 | $70 |
| Nestle Healthcare Nutrition Inc. | 3 | $59 |
| Esperion Therapeutics, Inc. | 2 | $52 |
| Abbott | 2 | $38 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $37 |
| Sanofi Pasteur Inc. | 2 | $31 |
| Seqirus USA Inc | 2 | $29 |
| Inogen, Inc. | 1 | $29 |
| Lundbeck LLC | 1 | $29 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Clarus Therapeutics Inc. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Novartis | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Philips North America LLC | 1 | $13 |
| Vertical Pharmaceuticals, LLC | 1 | $11 |
How this compares
$6,582 in reported general payments places this provider in the 95th percentile of 1,430 internal medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 82 | $74,717 |
| MounjaroTirzepatide | 50 | $70,274 |
| EliquisApixaban | 52 | $69,690 |
| JardianceEmpagliflozin | 29 | $42,268 |
| TrulicityDulaglutide | 22 | $30,866 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $29,436 |
| MyrbetriqMirabegron | 25 | $28,486 |
| OzempicSemaglutide | 14 | $23,818 |
| FarxigaDapagliflozin Propanediol | 14 | $23,561 |
| JanumetSitagliptin Phos/Metformin Hcl | 24 | $21,469 |
| ProliaDenosumab | 11 | $18,963 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 13 | $11,512 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $10,184 |
| Levothyroxine Sodium | 429 | $4,854 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 37 | $4,341 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $469 | $101,14172 claims |
| Johnson & JohnsonXarelto | $279 | $74,71782 claims |
| PfizerEliquis | $607 | $69,69052 claims |
| Boehringer IngelheimJardiance | $879 | $42,26829 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $667 | $39,62056 claims |
| Astellas Pharma US IncMyrbetriq | $259 | $28,48625 claims |
| Novo NordiskOzempic | $70 | $23,81814 claims |
| AstraZenecaFarxiga | $592 | $23,56114 claims |
| MerckJanumet | $190 | $21,46924 claims |
| AmgenProlia | $327 | $18,96311 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $103 | $11,51213 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $121 | $4,854429 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,430 internal medicine providers in Colorado.
Other internal medicine in Lakewood
- Kenneth CohenLakewood$4.5M
- Stanton ElziWheat Ridge$9.2M
- Jason HenryDenver$7.3M
- Luke WebbColorado Springs$2.1M
- Alexis LealAurora$2M
- Mauricio WaintrubAurora$1.3M
- Steven BrodieColorado Springs$883K
- Monica GrafalsAvon$673K
- Gilad GordonBoulder$476K
- Kathryn PolovitzParker$403K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.